{"id":494103,"date":"2021-05-17T08:05:15","date_gmt":"2021-05-17T12:05:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-reports-first-quarter-2021-financial-results-and-provides-a-corporate-update\/"},"modified":"2021-05-17T08:05:15","modified_gmt":"2021-05-17T12:05:15","slug":"vincerx-pharma-reports-first-quarter-2021-financial-results-and-provides-a-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vincerx-pharma-reports-first-quarter-2021-financial-results-and-provides-a-corporate-update\/","title":{"rendered":"Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update"},"content":{"rendered":"
\n

\n Phase 1b dose escalation study of VIP152 in patients with CLL relapsed\/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021<\/em>
\n \n <\/p>\n

\n First patient in Phase 1b Study of VIP152 in MYC-driven R\/R aggressive lymphomas and advanced solid tumors expected 2Q 2021<\/em>\n <\/p>\n

\n Phase 1 VIP152 dose-escalation safety and efficacy data in double-hit lymphoma to be presented at ASCO<\/em>\n <\/p>\n

PALO ALTO, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.<\/p>\n

\u201cThe clearance of Vincerx\u2019s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed\/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,\u201d said\u00a0Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. \u201cThis rapid execution is a testament to our team\u2019s capabilities, and builds upon our Phase 1b expansion study in patients with MYC-driven hematologic malignancies and solid tumors, expected to begin patient dosing in the second quarter. Both studies are part of our comprehensive clinical program, which leverages early signals of Phase 1 clinical activity to evaluate the potential of VIP152 in challenging oncology populations. We look forward to continued progress across these important milestones in the clinic, which will also include the presentation of Phase 1 data in patients with double-hit lymphoma at ASCO.\u201d<\/p>\n

Dr. Hamdy\u00a0continued, \u201cFor our preclinical assets, we were pleased to present compelling preclinical data on VIP236 at the AACR Annual Meeting, highlighting that VIP236 has the potential to provide potent, highly targeted antitumor activity to address the needs of patients with advanced and aggressive cancers. We remain focused on rapidly advancing our pipeline from a clinical and regulatory standpoint and look forward to providing further updates.\u201d<\/p>\n

\n Recent Highlights<\/strong>\n <\/p>\n